How much does TAGRISSO (Osimertinib Mesylate Tablets) Cost& price without insurance in China?
TAGRISSO® is the commercial brand name of Osimertinib Mesylate Tablets, an orally active third-generation EGFR tyrosine kinase inhibitor developed by AstraZeneca. It selectively inhibits EGFR activating mutations and the T790M resistance mutation, blocking downstream signaling pathways to suppress tumor cell proliferation.
Main Indications
First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
Treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC who have progressed on prior EGFR tyrosine kinase inhibitor therapy.
Common Side Effects
Common mild adverse reactions: Diarrhea, rash, dry skin, nail toxicity, and fatigue.
Laboratory abnormalities: Decreased platelet count, decreased lymphocyte count, and elevated liver enzymes.
Severe but uncommon risks: Interstitial lung disease, severe cutaneous adverse reactions, cardiomyopathy, and ocular toxicities.
Approval Status in China
TAGRISSO® (Osimertinib Mesylate Tablets) was officially approved for marketing in China in 2017. It is currently a prescription anti-tumor drug included in China’s Category B medical insurance.
Buy TAGRISSO (Osimertinib Mesylate Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
